Research on Endometrial Cancer: Risk factors, Classification and Treatment

Hiu Mei Luk

doi:10.62051/bsnbkf10

Authors

Hiu Mei Luk

DOI:

https://doi.org/10.62051/bsnbkf10

Keywords:

Endometrial Cancer; Risk Factors; Classification; Treatments.

Abstract

Endometrial cancer (EC) is one of the most common tumors of the female reproductive system. Its pathogenesis is complex, and the incidence tends to be younger, which seriously endangers women's health. Research has found that the calssification of EC is of great significance in clinical applications, including traditional types I (estrogen-dependent) and II (non-estrogen-dependent), as well as four molecular subtypes (POLE ultramutated, microsatellite instability hypermutated, copy number low, and copy number high). The risk factors affecting EC include genetic factors, obesity, menstrual irregularities, etc. In addition, significant progress has been made in the treatment of EC, with new breakthroughs in surgery, radiotherapy, chemotherapy, endocrine therapy, targeted therapy, etc. This article discusses risk factors, traditional classification, molecular classification and treatments of EC, in order to provide reference for clinical research on EC.

Downloads

Download data is not yet available.

References

Organization, W.H., I.A.f.R.o. Cancer, and W.H. Organization, Global cancer observatory. 2020.

Evans-Metcalf, E.R., et al., Profile of women 45 years of age and younger with endometrial cancer. Obstetrics & Gynecology, 1998. 91(3): p. 349-354.

Duska, L.R., et al., Endometrial cancer in women 40 years old or younger. Gynecologic oncology, 2001. 83(2): p. 388-393.

Leitao Jr, M.M. and R.R. Barakat, Endometrial cancer prevention, in Fundamentals of cancer prevention. 2013, Springer. p. 593-611.

Shaw, E., et al., Obesity and endometrial cancer. Obesity and cancer, 2016: p. 107-136.

Lu, K.H. and R.R. Broaddus, Endometrial Cancer. 2020. 383(21): p. 2053-2064.

ACOG, S., Practice bulletin no. 149: endometrial cancer. Obstet Gynecol, 2015. 125(4): p. 1006-26.

Aaltonen, M.H., et al., Comparison of lifestyle, hormonal and medical factors in women with sporadic and Lynch syndrome-associated endometrial cancer: a retrospective case-case study. Molecular and clinical oncology, 2017. 6(5): p. 758-764.

Bokhman, J.V., Two pathogenetic types of endometrial carcinoma. Gynecologic oncology, 1983. 15(1): p. 10-17.

Morice, P., et al., Endometrial cancer. The Lancet, 2016. 387(10023): p. 1094-1108.

Chi, D., et al., Principles and practice of gynecologic oncology. 2017: Lippincott Williams & Wilkins.

Bradley, C., et al., Endometrial cancer: molecular classification and future treatments. BMJ Medicine, 2022. 1(1): p. e000152.

Meng, X., et al., DNA polymerase ε relies on a unique domain for efficient replisome assembly and strand synthesis. Nature Communications, 2020. 11(1): p. 2437.

Vermij, L., et al., Incorporation of molecular characteristics into endometrial cancer management. Histopathology, 2020. 76(1): p. 52-63.

Arend, R.C., et al., Endometrial cancer: Molecular markers and management of advanced stage disease. Gynecologic oncology, 2018. 150(3): p. 569-580.

Köbel, M., et al., Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. International Journal of Gynecological Pathology, 2018. 38 Suppl 1: p. 1.

Concin, N., et al., ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecologic Cancer, 2021. 31(1).

Abu-Rustum, N., et al., Uterine Neoplasms, Version 1.2023, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 2023. 21(2): p. 181-209.

Randall, M.E., et al., Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of clinical oncology, 2006. 24(1): p. 36-44.

de Boer, S.M., et al., Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. The lancet oncology, 2018. 19(3): p. 295-309.

Lewin, S.N., et al., Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. Obstetrics & Gynecology, 2010. 116(5): p. 1141-1149.

Burke, W.M., et al., Endometrial cancer: a review and current management strategies: part II. Gynecologic oncology, 2014. 134(2): p. 393-402.

Bougherara, L., et al., Does lymphadenectomy improve survival in patients with intermediate risk endometrial cancer? A multicentric study from the FRANCOGYN Research Group. International Journal of Gynecologic Cancer, 2019. 29(2).

Emons, G., et al., Endometrial Cancer Lymphadenectomy Trial (ECLAT)(pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP. 6). International Journal of Gynecologic Cancer, 2021. 31(7).

Chiu, W.K., et al., Applications and Safety of Sentinel Lymph Node Biopsy in Endometrial Cancer. Journal of Clinical Medicine, 2022. 11(21): p. 6462.

Passarello, K., S. Kurian, and V. Villanueva, Endometrial Cancer: An Overview of Pathophysiology, Management, and Care. Seminars in Oncology Nursing, 2019. 35(2): p. 157-165.

Xiaomao Li, X.Y., Progress in the treatment of endometrial cancer. Chinese Journal of Modern Surgery, 2013. 17(1): p. 76-79.

Neri, M., et al., Systemic therapy for the treatment of endometrial cancer. Expert Opinion on Pharmacotherapy, 2019. 20(16): p. 2019-2032.

Fader, A.N., et al., Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. 2009. 115(10): p. 2119-2127.

Xiaofen Xing, X.L., Shuhua Qiao, Xiuhua Fan, Aimin Li, Xiangying Li, Exploration of Endocrine Cells and Endocrine Differentiation Mechanisms in Endometrial Cancer. Hebei Medical Journal, 2010. 32(24): p. 3542-3544.

Seoud, M., E.Å. Lundqvist, and K. Fujiwara, Targeted therapy in gynecologic cancers: Ready for prime time? International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2015. 131 Suppl 2: p. S150-2.